RC48-ADC in HER2-low Advanced Breast Cancer
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) as salvage treatment in patients with HER2-low advanced breast cancer who have received up to one previous chemotherapy for recurrent or metastatic disease without previous use of antibody-drug conjugate.
Advanced Breast Cancer
DRUG: Disitamab vedotin
Objective Response Rate (ORR), The percentage of subjects with complete remission (CR) or partial remission (PR) as the best response during the period from the beginning of the treatment to the progression of the disease or the completion of therapy (CR+PR)/Analysis of the total number of people.Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) was used to assess the objective tumor response., From the date of starting Disitamab Vedotin to the date of first documentation of progression or death (up to approximately 1 year)
Adverse events, Adverse events during Disitamab Vedotin regimen will be assessed according to the NCI CTCAE v5.0., From the date of starting Disitamab Vedotin to the end of the treatment (up to approximately 1 year)
Subjects with HER2-low advanced breast cancer were treated with Disitamab vedotin as salvage treatment. ORR, PFS, OS and AE were assessed during the trial. HER2-low status is defined as IHC1+ or IHC2+ with negative FISH test.